SEATTLE — In this Healio Video Perspective from OIS Retina, Megan Baldwin, PhD, provides an update on OPT-302, now called sozinibercept, for the treatment of neovascular age-related macular degeneration.
Sozinibercept is a novel VEGF-C/D “trap” inhibitor designed to provide patients with a greater visual acuity benefit on top of standard-of-care treatment, Baldwin said.
“We are recruiting patients globally, and we are really excited in the short term to be moving the program forward and hope to really demonstrate greater benefits for patients,” she said.